Andere talen SofWave Medical Ltd.

Aandelen

SOFW

IL0011754392

Vertraagde tijd TEL AVIV STOCK EXCHANGE Andere beurzen 10:17:27 21-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.678 ^ILa	-0,83%		-6,36%	+22,30%

09/05	SofWave Medical Ltd. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
06/03	SofWave Medical Ltd. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights	09/05
SofWave Medical : Presentation- Q1 2024 Summary-May 2024	09/05
SofWave Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Sofwave Medical to Participate in the Needham 23rd Annual Healthcare Conference	28/03
Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	06/03
SofWave Medical : Presentation- Investor Meeting-March 2024	06/03
SofWave Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting	04/03
Sofwave Medical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference	28/02
Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer	12/02
SofWave Medical Ltd. Appoints James Bartholomeusz as Chief Innovation Officer	12/02
Sofwave Medical Receives 510(k) Marketing Clearance for Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology	03/01
Sofwave Medical Receives 510(K) Marketing Clearance for Pure Impact Strength and Muscle Toning Body Module Utilizing Plyopulse EMS Technology	03/01
Sofwave Medical Receives FDA Clearance of SUPERB™ Technology For Improvement of the Appearance of Skin Laxity on the Upper Arm	26/12
SofWave Medical Ltd. Receives FDA Clearance of Superb?? Technology for Improvement of the Appearance of Skin Laxity on the Upper Arm	26/12
Sofwave Earns Frost & Sullivan's 2023 North American Technology Innovation Leadership Award for Developing a Sophisticated Skin Tightening Ultrasound Technology with Minimal Downtime	20/11
Sofwave Medical Reports Third Quarter 2023 Financial Results and Business Highlights	08/11
SofWave Medical Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars	30-08-23
Sofwave Medical Announces FDA Clearance of SUPERB? Technology For Treatment of Acne Scars	30-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SofWave Medical Ltd.

Aandelen

SOFW

IL0011754392

Andere talen

Filters